title: Neurological complications of sclerotherapy for varicose veins.
abstract: BACKGROUND
  Sclerotherapy has been shown to be an effective and increasingly popular therapeutic strategy for the treatment of varicose veins. However, recent reports of serious side effects, including cerebrovascular accidents (CVA) and transient ischemic attacks (TIA), as well as speech and visual disturbances, have caused serious concern regarding its use. This review evaluated the reported incidences of neurological side effects associated with the use of sclerotherapy.
  
  
  METHODS
  A systematic search of the data bases MEDLINE, OVID Embase, and Google Scholar was undertaken by two independent reviewers. Articles reporting neurological side effects in humans following foam and liquid sclerotherapy were included; animal studies, laboratory studies, and review articles were excluded. Additional references were also obtained using the related articles function.
  
  
  RESULTS
  The search yielded 1023 articles, of which 41 studies were found to meet the inclusion criteria. A total of 10,819 patients undergoing sclerotherapy were reviewed. There were 12 case reports of CVA with confirmatory brain imaging and nine reports of TIA. There were 97 (0.90%) reports of neurological events overall, including TIA, visual and speech disturbances, and 29 cases of reported migraine (0.27%). Symptoms occurred at times ranging from minutes to several days following sclerotherapy. Eleven patients with TIA or CVA were found to have a right to left cardiac shunt, usually a patent foramen ovale.
  
  
  CONCLUSIONS
  Neurological side effects following sclerotherapy are a rare occurrence; however, CVA associated with the use of sclerotherapy is clearly documented. The pathologic mechanisms resulting in CVA are likely to be different to those leading to migraine and visual disturbances; however, care should be exercised in patient selection, particularly in those with known cardiac defects.
authors.affiliation: Academic Section of Vascular Surgery, Imperial College School of Medicine, Charing Cross Hospital, London, United Kingdom.
authors.forename: Tharsi
authors.initials: T
authors.lastname: Sarvananthan
authors.forename: Amanda Claire
authors.initials: AC
authors.lastname: Shepherd
authors.forename: Torsten
authors.initials: T
authors.lastname: Willenberg
authors.forename: Alun Huw
authors.initials: AH
authors.lastname: Davies
mesh_terms: D002561:Cerebrovascular Disorders / Q000209:etiology; D006801:Humans; D008881:Migraine Disorders / Q000209:etiology; D009422:Nervous System Diseases / Q000209:etiology*; D018570:Risk Assessment; D012307:Risk Factors; D012597:Sclerosing Solutions / Q000009:adverse effects*; D015911:Sclerotherapy / Q000009:adverse effects*; D013064:Speech Disorders / Q000209:etiology; D013997:Time Factors; D014648:Varicose Veins / Q000628:therapy*; D014786:Vision Disorders / Q000209:etiology
chemical_list: D012597:Sclerosing Solutions